Morgan Stanley Downgrades TScan Therapeutics (NASDAQ:TCRX) to Equal Weight

TScan Therapeutics (NASDAQ:TCRX) was downgraded by research analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research report issued on Friday, MarketBeat reports.

TCRX has been the subject of a number of other research reports. HC Wainwright cut their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday. BTIG Research lowered TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Needham & Company LLC lowered their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. Finally, Wedbush restated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.60.

TScan Therapeutics Stock Performance

NASDAQ TCRX remained flat at $1.13 during trading on Friday. The company’s stock had a trading volume of 248,056 shares, compared to its average volume of 507,896. The firm has a market cap of $64.13 million, a P/E ratio of -1.01 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06. The company has a 50 day moving average price of $1.85 and a 200-day moving average price of $1.70. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $4.94.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.07. The firm had revenue of $2.51 million for the quarter, compared to analyst estimates of $1.98 million. TScan Therapeutics had a negative return on equity of 67.61% and a negative net margin of 1,692.96%. As a group, equities analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC bought a new stake in shares of TScan Therapeutics in the first quarter valued at approximately $49,000. Checkpoint Capital L.P. lifted its position in shares of TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock worth $2,784,000 after acquiring an additional 261,663 shares in the last quarter. BVF Inc. IL boosted its stake in TScan Therapeutics by 63.6% in the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock worth $6,747,000 after purchasing an additional 1,900,000 shares during the period. Goldman Sachs Group Inc. grew its stake in TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of TScan Therapeutics by 149.4% during the 1st quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after acquiring an additional 31,481 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.